Friday, July 10, 2026

pharma · Chronic Spontaneous Urticaria · Asthma

Novartis India

Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP

Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Clinical program

Glycopyrronium bromide

Phase 3 · small molecule · Chronic Obstructive Pulmonary Disease

Glycopyrronium bromide for Chronic Obstructive Pulmonary Disease is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Novartis Pharmaceuticals projects Phase 3 small molecule completed

Internal code CNVA237A2303

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Modality
small_molecule
Indication
Chronic Obstructive Pulmonary Disease
Status
completed
Trials
1